Effectiveness of Bailing capsules in the treatment of lupus nephritis: A meta‑analysis

Li,Yue; Xu,Tianhua; Qiu,Xiaobo; Tian,Binyao; Bi,Chao; Yao,Li

doi:10.3892/mmr.2020.11293

Effectiveness of Bailing capsules in the treatment of lupus nephritis: A meta‑analysis

Authors:
- Yue Li
- Tianhua Xu
- Xiaobo Qiu
- Binyao Tian
- Chao Bi
- Li Yao
View Affiliations

Affiliations: Department of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310029, P.R. China
Published online on: June 30, 2020 https://doi.org/10.3892/mmr.2020.11293
Pages: 2132-2140

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have explored the treatment of lupus nephritis with Bailing capsules; however, due to limited sample sizes and inconsistent results across these studies, no definitive conclusions have been drawn. Thus, the present study aimed to provide evidence for the effectiveness of Bailing capsules in the treatment of lupus nephritis. To obtain relevant clinical studies (published before 20 July 2019), PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, WanFang and the Chinese Biomedical Literature Database were searched, and relevant studies concerning the use of Bailing capsules for treating lupus nephritis were selected. The extracted data were general characteristics such as the first author, publication year, study year, follow‑up time, age, sex, course of the disease and a number of outcome indicators. These included systemic lupus erythematosus disease activity index (SLEDAI) score, serum albumin (Alb), 24‑h urinary protein, serum creatinine, anti‑ds‑DNAIgM, complement component 3 (C3), and the number of effective treatments and complications. Meta‑analysis was performed using R‑3.12 software. Publication bias was assessed using Egger's test. A total of 14 studies comprising 1,301 participants were combined for analysis in the present study. The results demonstrated that with the exception of anti‑ds‑DNAIgM and complement C3, other indicators, such as SLEDAI score, Alb, 24‑h urinary protein, serum creatinine, and the number of effective treatments and complications) in the Bailing capsule treatment group were improved compared with those in the control group. The results of the present meta‑analysis suggested that Bailing capsules may be effective in the treatment of lupus nephritis.

View Figures

View References

1	Sun L, Zou LX, Han YC, Wu L, Chen T, Zhu DD and Hu P: A20 overexpression exerts protective effects on podocyte injury in lupus nephritis by downregulating UCH-L1. J Cell Physiol. 234:16191–16204. 2019. View Article : Google Scholar
2	Mu Q, Zhang H, Liao X, Lin K, Liu H, Edwards MR, Ahmed SA, Yuan R, Li L, Cecere TE, et al: Control of lupus nephritis by changes of gut microbiota. Microbiome. 5:732017. View Article : Google Scholar : PubMed/NCBI
3	Miranda-Hernández D, Cruz-Reyes C, Angeles U, Jara LJ and Saavedra MA: Prognostic factors for treatment response in patients with lupus nephritis. Reumatol Clin. 10:164–169. 2014.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
4	Rees F, Doherty M, Grainge MJ, Lanyon P and Zhang W: The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. Rheumatology (Oxford). 56:1945–1961. 2017. View Article : Google Scholar : PubMed/NCBI
5	Hogan J and Appel GB: Update on the treatment of lupus nephritis. Curr Opin Nephrol Hypertens. 22:224–230. 2013. View Article : Google Scholar : PubMed/NCBI
6	Okpechi IG, Gcelu A and Ameh OI: Lupus nephritis: A simplified approach to diagnosis and treatment in South Africa. South African Medical J. 105:1071–1074. 2015. View Article : Google Scholar
7	Chan TM: Treatment of severe lupus nephritis: The new horizon. Nat Rev Nephrol. 11:46–61. 2015. View Article : Google Scholar : PubMed/NCBI
8	Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, Nagaraja H, Indrakanti D and Rovin BH: Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 32:1338–1344. 2015. View Article : Google Scholar
9	Ren HJ, Sun YL and Yuan B: Chinese patent medicine Bailing capsule for treating lupus nephritis: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 98:e170412019. View Article : Google Scholar : PubMed/NCBI
10	Xu H and Li S: Pharmacological effects of Bailing capsule and its application in lung disease research. Zhongguo Zhong Yao Za Zhi. 35:2777–2781. 2010.(In Chinese). PubMed/NCBI
11	Li S and Wang L: Clinical observation on the therapeutic effect of Corbrin Capsule in the treatment of lupus nephritis. Chin Commun Doctors. 33:61–62. 2017.(In Chinese).
12	Zhou L, Zhang B, Yao C and Liao A: Clinical research of Bailing capsules on change of cellular immunity in lupus nephritis. Chin Pharmacist. (4): 289–290. 2004.(In Chinese).
13	Bai XM, Li H, Li XD and Li Y: Clinical study on corbrin capsules combined with cyclophosphamide in treatment of lupus nephritis. Drugs Clin. 34:1181–1184. 2019.(In Chinese).
14	Li XY, Li FX and Li B: Clinical study on corbrin capsules combined with leflunomide and prednisone in treatment of lupus nephritis. Drugs Clin. 34:154–158. 2019.(In Chinese).
15	Higgins JP and Green S: Cochrane handbook for systematic reviews of interventions: Cochrane Book Series. The Cochrane Collaboration; 2008
16	Liu T, Xu QE, Zhang CH and Zhang P: Occupational exposure to methylene chloride and risk of cancer: A meta-analysis. Cancer Causes Control. 24:2037–2049. 2013. View Article : Google Scholar : PubMed/NCBI
17	Lau J, Ioannidis JP and Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med. 127:820–826. 1997. View Article : Google Scholar : PubMed/NCBI
18	Feng RN, Zhao C, Sun CH and Li Y: Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS One. 6:e184802011. View Article : Google Scholar : PubMed/NCBI
19	Ma E, Wang H, Guo J, Tian R and Wei L: The association between the rs11196218A/G polymorphism of the TCF7L2 gene and type 2 diabetes in the Chinese Han population: A meta-analysis. Clinics (Sao Paulo). 70:593–599. 2015. View Article : Google Scholar : PubMed/NCBI
20	Seagroatt V and Stratton I: Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate. BMJ. 316:469–471. 1997.
21	He Y, Huang JP, Wu RY and Tan F: Observation of clinical effect of Bailing capsule combined with low molecular weight heparin for the treatment of lupus of nephritis. Asia Pacific Tradit Med. 9:207–208. 2013.(In Chinese).
22	Liu DM, Wang CH and Li XP: Clinical analysis of 65 cases of lupus nephritis treated by Bailing capsule. Chin Commun Doctors. 21. 2006.(In Chinese).
23	Wang GH, Su XD and Wu Y: Clinical study on Corbrin Capsules combined with prednisone in treatment of lupus nephritis. Drugs Clin. 33:2372–2376. 2018.(In Chinese).
24	Wang JB: Clinical effect of boling capsule combined with prednisone in the treatment of lupus nephritis SLEDAI scoring analysis. Chin J Mod Drug Appl. 121–122. 2019.(In Chinese).
25	Wang XY, Wang GJ, Zhang XX, Gong YN, Li YS, Ma S, Xiao J and Zhao ZZ: Clinical study on Bailing capsules combined with tacrolimus in treatment of lupus nephritis. Drugs Clin. 32:1065–1069. 2017.(In Chinese).
26	Wu G: Methyprednisolone with Bailing capsule in treatment of lupus nephritis. J Medical Forum. 28:38–39. 2007.(In Chinese).
27	Yang ZH, Liu B, Lu J, Hou XX and Yin J: A multicenter prospective study of the effect of Bailing capsules on clinical efficacy and infection rate in the patients with lupus nephritis. Heilongjiang Med J. 28:1205–1208. 2015.(In Chinese).
28	Zhu PJ, Ke SS and Xu F: Effect of Bailing capsules on interleukin-2, complement and infection rate in patients with lupus nephritis. Chin J Mod Appl Pharm. 33:364–368. 2015.(In Chinese).
29	Xu DD: Observation on the efficacy of boling capsule combined with tacrolimus in the treatment of lupus nephritis. Mod Diagn Treat. 29:2888–2890. 2018.
30	Wang WX: Study on the combination of boling capsule and tacrolimus in the treatment of lupus nephritis. Chin J Mod Drug Appl. 12:112–113. 2018.
31	Shu Q, Tan F, Huang LH and Peng J: Effect of Bailing capsules on macrophage function by regulating miR- 127 expression in lupus nephritis patients. Tradit Chinese Drug Res Clin Pharmacol. 30:733–738. 2019.(In Chinese).
32	Feng D: The correlation analysis of urine microalbumin /urine creatinine and 24 h urine proteinquantification in patients with chronic nephritis. Laborat Med Clin. 14:1942017.(In Chinese).
33	Zhang H and Ge X: Significance of Cys C, BUN and sCr level detection in assessment of early renal damage of acute glomerulonephritis. J Hainan Med Univ. 22:447–449. 2016.(In Chinese).
34	Gladman DD, Ibañez D and Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 29:288–291. 2002.PubMed/NCBI
35	Wang BL, Li QY and Huang WL: Assessment of renal injury degree in patients with nephritis by β 2-m, AIb, IgG, and α 1-m. J Radioimmunol. 14:91–93. 2001.
36	Szulińska M, Skrypnik D, Ratajczak M, Karolkiewicz J, Madry E, Musialik K, Walkowiak J, Jakubowski H and Bogdański P: Effects of endurance and endurance-strength exercise on renal function in abdominally obese women with renal hyperfiltration: A prospective randomized trial. Biomed Environ Sci. 29:706–712. 2016.PubMed/NCBI